.jpg "Chimerix (NASDAQ: CMRX)")
In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Chimerix (NASDAQ: CMRX), with a price target of $6. The company’s shares opened today at $3.55, close to its 52-week low of $3.53.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 10.1% and a 51.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Chimerix has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.94 and a one-year low of $3.53. Currently, Chimerix has an average volume of 169.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox.
Read More on CMRX:
